Genmab A/S (NASDAQ:GMAB) has been assigned a consensus rating of “Hold” from the sixteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $44.17.
Several research firms recently weighed in on GMAB. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Genmab A/S in a research note on Friday, August 20th. TheStreet raised shares of Genmab A/S from a “c” rating to a “b” rating in a research report on Monday, May 24th. Barclays reaffirmed an “overweight” rating on shares of Genmab A/S in a research report on Thursday, August 12th. Societe Generale reaffirmed a “sell” rating on shares of Genmab A/S in a research report on Monday, August 16th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Genmab A/S in a research report on Thursday, August 12th.
Shares of NASDAQ:GMAB traded down $0.21 during midday trading on Tuesday, hitting $43.81. The stock had a trading volume of 328,304 shares, compared to its average volume of 522,401. Genmab A/S has a 12 month low of $30.10 and a 12 month high of $49.07. The business’s 50-day simple moving average is $45.55 and its 200-day simple moving average is $40.14. The company has a market cap of $28.77 billion, a P/E ratio of 70.66, a PEG ratio of 2.94 and a beta of 0.89.
About Genmab A/S
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
See Also: Blue-Chip Stocks
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.